ArticlePublic health challenges2026
Studying the Comorbidity of Impaired eGFR With Diabetes, Hypertension, and Cardiovascular Diseases in the Tabari Cohort Population.
Article in Public health challenges, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study examines the prevalence and interrelationships of reduced estimated glomerular filtration rate (eGFR) with diabetes mellitus (DM), hypertension (HTN), and cardiovascular diseases (CVDs) within the Tabari cohort population. Methods: A cross-sectional analysis was performed using data from the Tabari cohort, part of the large Prospective Epidemiological Research Studies in Iran (PERSIAN) cohort study. Participants aged 35-70, excluding those with end-stage renal disease or cancer, were included. Reduced eGFR was defined on the basis of a single baseline measurement of eGFR, categorized into G1-G4 stages. The presence of DM, HTN, and CVD was recorded along with demographic and clinical parameters. Statistical analyses included chi-square tests, Results: Of 9939 participants, 25.5% had reduced eGFR, with prevalence rates of 4.8%, 69.7%, 25.4%, and 0.1% for G1, G2, G3, and G4, respectively. Reduced eGFR was more common with increasing age, in females, and in single/divorced/widowed individuals ( Conclusion: A high comorbid prevalence of HTN, DM, and CVD was observed among individuals with reduced eGFR in the Tabari cohort, with HTN emerging as the strongest independent predictor. These findings highlight the importance of early detection and integrated management strategies to prevent further decline in kidney function and associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.